Oxbow Advisors LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Oxbow Advisors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 5,247 shares of the biopharmaceutical company’s stock, valued at approximately $2,950,000.

Several other institutional investors also recently bought and sold shares of REGN. Mn Services Vermogensbeheer B.V. lifted its position in Regeneron Pharmaceuticals by 1.3% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 40,500 shares of the biopharmaceutical company’s stock valued at $22,772,000 after purchasing an additional 500 shares during the last quarter. Deseret Mutual Benefit Administrators grew its holdings in shares of Regeneron Pharmaceuticals by 18.4% in the third quarter. Deseret Mutual Benefit Administrators now owns 681 shares of the biopharmaceutical company’s stock worth $383,000 after purchasing an additional 106 shares during the last quarter. UniSuper Management Pty Ltd increased its stake in shares of Regeneron Pharmaceuticals by 14.2% in the third quarter. UniSuper Management Pty Ltd now owns 9,559 shares of the biopharmaceutical company’s stock worth $5,375,000 after buying an additional 1,191 shares during the period. Delta Financial Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 2.9% in the third quarter. Delta Financial Advisors LLC now owns 1,478 shares of the biopharmaceutical company’s stock worth $831,000 after buying an additional 41 shares during the period. Finally, Grandfield & Dodd LLC raised its holdings in Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Grandfield & Dodd LLC now owns 36,451 shares of the biopharmaceutical company’s stock valued at $20,495,000 after buying an additional 1,246 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha previews Regeneron’s Q4 and expects an earnings beat and a strong 2026, maintaining a Buy rating and noting the shares have rallied >16% since the author’s prior note — this supports upside if results meet or exceed guidance. Read More.
• Positive Sentiment: Zacks says Regeneron has the right setup to beat upcoming earnings (Earnings “ESP”/estimates upside), which could trigger further upside if the company reports above-consensus results. Read More.
• Positive Sentiment: Evercore ISI raised its price target on REGN from $750 to $875 and kept an “outperform” call — a material analyst upgrade that increases implied upside and can support buying interest. Read More.
• Positive Sentiment: MarketBeat aggregation (reported on DefenseWorld/American Banking News) shows an average analyst rating of “Moderate Buy” across ~28 brokerages, indicating broad analyst conviction that could limit downside absent a negative print. Read More.
• Neutral Sentiment: Reminders that Regeneron will release quarterly earnings on Friday — serves as the immediate event risk/reward driver; expect heightened volume and larger intraday moves around the report. Read More.
• Neutral Sentiment: Zacks compares REGN with Illumina (ILMN) on valuation — useful context for investors weighing sector alternatives, but not an immediate catalyst for REGN alone. Read More.
• Neutral Sentiment: A Zacks piece highlights two medical names that could beat earnings (including REGN), which reinforces market attention on earnings-season upside but is not new company-specific data. Read More.

Regeneron Pharmaceuticals Stock Down 0.3%

REGN traded down $1.96 on Friday, hitting $753.55. The company had a trading volume of 721,001 shares, compared to its average volume of 734,749. The stock has a fifty day simple moving average of $755.38 and a 200-day simple moving average of $643.06. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The firm has a market capitalization of $79.20 billion, a P/E ratio of 18.04, a P/E/G ratio of 1.97 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $12.46 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 8th. Evercore ISI boosted their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Cantor Fitzgerald lifted their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $794.70.

Insider Transactions at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,431 shares of company stock valued at $5,733,521 in the last three months. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.